Physician profile
Melvin Coats
NPI 1376599159
$556.63
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.06 · 2020: $40.21 · 2021: $223 · 2022: $180 · 2023: $39.79 · 2024: $22.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $62.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $62.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $116.15 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $99.08 | 2020-2022 | |
| Abbott Laboratories | $53.44 | 2021-2023 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $43.81 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $43.17 | 2022-2023 | Gvoke Hypopen |
| Novo Nordisk INC | $38.87 | 2022 | |
| Pfizer INC. | $36.09 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $24.90 | 2022 | |
| Boston Scientific Corporation | $23.24 | 2020 | |
| Sumitomo Pharma America, INC. | $22.30 | 2024 | Gemtesa |
| Kci USA, INC. | $21.07 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.84 | 2019 | |
| Glaxosmithkline, LLC. | $14.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melvin Coats listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.